Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency

NCT03548220 is registered in ClinicalTrials.gov with Agios Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03548220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03548220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency
Lead sponsor
Agios Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 9, 2018
Completion date
October 9, 2020
Enrollment
80 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, hemolytic, pyruvate kinase deficiency